Methods and compositions for predicting and treating uveal melanoma
AssigneesInserm (Institut National De La Sante Et De La Recherche Medicale), Université CôTe D'Azur
InventorsRobert BALLOTTI, Thomas STRUB, Charlotte PANDIANI, Corine BERTOLOTTO-BALLOTTI
Life of this patent
Estimating the term…
Abstract
Here, in multi-scale analyses using single-cell RNA sequencing of six different primary uveal melanomas, inventors uncover a previously unrecognized intratumor heterogeneity at the genetic and transcriptomic level. They identify distinct transcriptional cell states and diverse tumor-associated populations in a subset of primary uveal melanomas.
Claims13
A method for predicting the survival time of a subject suffering from uveal melanoma and/or metastatic uveal melanoma and treating the subject, comprising the steps of:
- i) determining a score of SPP1, EMCN, SYNPR, CTC-340A15.2, HPGD, MTRNR2L8, PDE4DIP, COX6A2, AHCYL2, GSTA3 and H3F3A in a biological sample obtained from the subject;
- ii) administering, to a subject identified as having a score of SPP1, EMCN, SYNPR, CTC-340A15.2, HPGD, MTRNR2L8, PDE4DIP, COX6A2, AHCYL2, GSTA3 and H3F3A that is higher than a corresponding predetermined reference value, a therapeutically effective amount of an activator of SPP1, EMCN, SYNPR, CTC-340A15.2, HPGD, MTRNR2L8, PDE4DIP, COX6A2, AHCYL2, GSTA3 and H3F3A.
A method for treating uveal melanoma and/or metastatic uveal melanoma in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an activator of SPP1, EMCN, SYNPR, CTC-340A15.2, HPGD, MTRNR2L8, PDE4DIP, COX6A2, AHCYL2, GSTA3 and/or H3F3A.
A composition comprising i) an inhibitor of SPP1, EMCN, SYNPR, CTC-340A15.2, HPGD, MTRNR2L8, PDE4DIP, COX6A2, AHCYL2, GSTA3 and/or H3F3A, and ii) an immune checkpoint inhibitor, a BRAF inhibitor and/or a MEK inhibitor.
Dependencies are inferred from the claim text.